phrykt

Tempest Therapeutics, Inc. (TPST): who owns it and who trades it

As of Nov 10, 2026, TPST insiders reported 1 purchase worth $500K in the last 12 months. The largest buyer was Matthew Angel (CEO), with $500K.

Latest filing Nov 10, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, TPST insiders reported $500K of open-market purchases and $0 of sales.

Purchases, 12 months
$500K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Mar 24, 2026
Filed Mar 25, 2026

Purchases and sales by month

$500K$500KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Mar 24, 2026Matthew AngelCEOPurchase231,482$2.16$500KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Matthew AngelCEO and President, Director, 10% owner$500K–Mar 24, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TPST short interest

241,168 TPST shares are sold short. Over the last 12 reports the number of shares short went down 40%.

As of Oct 30, 2026, 241,168 TPST shares were sold short, down 22.9% from the report before. At the average daily volume of 128,299 shares, buying them all back would take about 1.9 trading days (days to cover).

Shares short, % of all shares

4.24%May 15Sep 304.66%

Days to cover

1.9May 15Oct 303.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026241,168–-23%128,2991.9
Oct 15, 2026312,948–-49%361,4621.0
Sep 30, 2026608,4344.24%+74%11.20M1.0
Sep 15, 2026350,4152.44%-8%2.88M1.0
Aug 31, 2026381,5802.66%+2%188,1652.0
Aug 14, 2026373,7822.61%+40%372,3981.0
Jul 31, 2026266,9011.86%-16%191,2631.4
Jul 15, 2026317,6602.21%+12%158,8282.0
Jun 30, 2026284,7641.99%+38%242,6821.2
Jun 15, 2026205,7071.43%-40%100,8482.0
May 29, 2026341,3342.38%-15%96,2633.5
May 15, 2026401,1282.80%+2%142,2782.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Tempest Therapeutics company events

Tempest Therapeutics filed 32 reports on Form 8-K in the last 12 months, 13 of them about an important change (leadership, control, listing). The latest was on Nov 10, 2026.

  1. Nov 10, 2026VoteReported shareholder vote results. Filing
  2. Nov 6, 2026ListingTempest Therapeutics, Inc., a Delaware corporation, received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum… Filing
  3. Oct 30, 2026LeadershipMs. Constance Ames confirmed to Tempest Therapeutics, Inc. that she would be resigning from her position as Chief Financial Officer of the Company and from any and all other positions she holds with the Company for personal considerations unrelated to the Company, effective immediately. Filing
  4. Oct 20, 2026AnnouncementOf this Current Report on Form 8-K is incorporated herein by reference. Filing
  5. Oct 19, 2026LeadershipThe Board of Directors of Tempest Therapeutics, Inc. appointed Mr. John Frederick as a Class III director of the Board. Filing
  6. Sep 28, 2026LeadershipThe Board appointed Ms. Nancy Freda-Smith as Class III director to fill a vacancy on the Board. Filing
  7. Sep 17, 2026AgreementTempest Therapeutics, Inc. entered into an exclusive collaboration, option and license agreement with Heibei Senlang Biotechnology Co., Ltd., a PRC company, under which Senlang granted the Company an exclusive option, exercisable within four months, to obtain an exclusive, royalty-bearing… Filing
  8. Sep 16, 2026AnnouncementOf this Current Report on Form 8-K is incorporated herein by reference. Filing
  9. Sep 15, 2026AgreementTempest Therapeutics, Inc. entered into a securities purchase agreement with an institutional investor, pursuant to which the Company issued and sold in a private placement pre-funded warrants to purchase up to 3,105,591 shares of the Company’s common stock, par value $0.001 per share accompanied… Filing
  10. Aug 24, 2026LeadershipMr. Justin Trojanowski notified Tempest Therapeutics, Inc. of his decision to resign from his positions as Principal Financial Officer and Principal Accounting Officer of the Company, and from any and all other positions he holds with the Company, effective as of September 1, 2026. Filing
  11. Aug 18, 2026AnnouncementOf this Current Report on Form 8-K is incorporated herein by reference. Filing
  12. Aug 13, 2026ResultsReleased financial results. Filing
  13. Aug 13, 2026AgreementTempest Therapeutics, Inc., a Delaware corporation, entered into a purchase agreement and a registration rights agreement with Lincoln Park Capital Fund, LLC, pursuant to which Lincoln Park has committed to purchase up to $50.0 million of the Company’s common stock, par value $0.001 per share, such… Filing
  14. Jul 28, 2026AnnouncementOf this Current Report on Form 8-K is incorporated herein by reference. Filing
  15. Jul 22, 2026AgreementTempest Therapeutics, Inc., a Delaware corporation, entered into a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd., a company organized under the laws of the People’s Republic of China. Filing
  16. Jun 23, 2026VoteReported shareholder vote results. Filing
  17. Jun 4, 2026LeadershipMr. Nicholas Maestas notified Tempest Therapeutics, Inc. of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company, effective as of June 5, 2026. Filing
  18. Jun 2, 2026AgreementTempest Therapeutics, Inc., a Delaware corporation, entered into a warrant exercise and inducement offer letter agreement with a holder of certain existing warrants to purchase shares of the Company’s common stock that the Company originally issued in November 2025 at an original exercise price of… Filing
  19. May 29, 2026LeadershipMs. Simantov notified Tempest Therapeutics, Inc. of her resignation from the Board of Directors of the Company, effective as of such date. Filing
  20. May 22, 2026ListingTempest Therapeutics, Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Filing
  21. May 22, 2026LeadershipEach of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. of his or her resignation from the Board of Directors of the Company, effective as of such date. Filing
  22. May 14, 2026ResultsReleased financial results. Filing
  23. May 6, 2026AnnouncementThe Company issued a press release entitled “Tempest Presents Clinical Update at ISCT 2026 Annual Meeting.” A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Filing
  24. Mar 30, 2026ResultsReleased financial results. Filing
  25. Mar 23, 2026AgreementTempest Therapeutics, Inc. entered into a securities purchase agreement with (a) two institutional investors and (b) Factor Bioscience Inc. (the “ Strategic Investor ” and, together with the Institutional Investors, each, an “ Investor ” and, together, the “ Investors ”), pursuant to which the… Filing
  26. Feb 25, 2026AnnouncementThe Company issued a press release entitled “Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026.” A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Filing
  27. Feb 11, 2026AnnouncementShared information with investors. Filing
  28. Feb 6, 2026ControlThe information contained in the Introductory Note and Item 2.01 of this Form 8-K is incorporated by reference into this Item 5.01. Filing
  29. Jan 28, 2026LeadershipThe Company’s stockholders approved Amendment No. 1 to the Company’s Amended and Restated 2023 Equity Incentive Plan to increase the number of shares of the Company’s common stock issuable under such plan by 1,410,000 shares. Filing
  30. Jan 9, 2026ListingAs previously disclosed in Tempest Therapeutics, Inc.’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on December 31, 2025, the Company has scheduled its 2025 Annual Meeting of Stockholders to be held on January 27, 2026. Filing
  31. Nov 26, 2025AnnouncementBelow which is hereby incorporated in this Item 3.02 by reference. Filing
  32. Nov 19, 2025LeadershipMatt Angel, Ph.D. In connection with the Closing of the Contemplated Transaction, Dr. Angel will be appointed to serve as the Company’s President and Chief Executive Officer, replacing Mr. Brady in such capacities, and as a member of the Company’s board of directors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Tempest Therapeutics financials

Questions about Tempest Therapeutics, Inc. (TPST) stock

Are TPST insiders buying or selling?

In the last 12 months, TPST insiders reported 1 open-market purchase worth $500K and no sales. The latest trade was on Mar 24, 2026. See every trade.

What is the short interest in TPST?

As of Oct 30, 2026, 241,168 TPST shares were sold short, down 22.9% from the report before. At the average daily volume of 128,299 shares, buying them all back would take about 1.9 trading days (days to cover). See the history.

Executive pay

Tempest Therapeutics's chief executive was paid a total of $2.3M for the year ended Dec 31, 2025, up 23% from $1.9M the year before. In the last 12 months, Tempest Therapeutics's executives and directors bought $500K of stock on the open market and sold none.

Chief executive, total pay$2.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.